Clinical Genomics Laboratory

Publications

Found 13 results
Author [ Title(Desc)] Type Year
Filters: First Letter Of Last Name is F  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
C
Huang L, Fernandes H, Zia H, Tavassoli P, Rennert H, Pisapia D, Imielinski M, Sboner A, Rubin MA, Kluk M et al..  2017.  The cancer precision medicine knowledge base for structured clinical-grade mutations and interpretations.. J Am Med Inform Assoc. 24(3):513-519.
Fernandez EM, Eng K, Beg S, Beltran H, Faltas BM, Mosquera JMiguel, Nanus DM, Pisapia DJ, Rao RA, Robinson BD et al..  2019.  Cancer-Specific Thresholds Adjust for Whole Exome Sequencing-based Tumor Mutational Burden Distribution.. JCO Precis Oncol. 3
Fernandez EM, Eng K, Beg S, Beltran H, Faltas BM, Mosquera JMiguel, Nanus DM, Pisapia DJ, Rao RA, Robinson BD et al..  2019.  Cancer-Specific Thresholds Adjust for Whole Exome Sequencing-based Tumor Mutational Burden Distribution.. JCO Precis Oncol. 3
Khorrami M, Prasanna P, Gupta A, Patil P, Velu PD, Thawani R, Corredor G, Alilou M, Bera K, Fu P et al..  2020.  Changes in CT Radiomic Features Associated with Lymphocyte Distribution Predict Overall Survival and Response to Immunotherapy in Non-Small Cell Lung Cancer.. Cancer Immunol Res. 8(1):108-119.
Khorrami M, Prasanna P, Gupta A, Patil P, Velu PD, Thawani R, Corredor G, Alilou M, Bera K, Fu P et al..  2020.  Changes in CT Radiomic Features Associated with Lymphocyte Distribution Predict Overall Survival and Response to Immunotherapy in Non-Small Cell Lung Cancer.. Cancer Immunol Res. 8(1):108-119.
Schwartz GW, Manning B, Zhou Y, Velu P, Bigdeli A, Astles R, Lehman AW, Morrissette JJD, Perl AE, Li M et al..  2019.  Classes of ITD Predict Outcomes in AML Patients Treated with FLT3 Inhibitors.. Clin Cancer Res. 25(2):573-583.
D
Rennert H, Eng K, Zhang T, Tan A, Xiang J, Romanel A, Kim R, Tam W, Liu Y-C, Bhinder B et al..  2016.  Development and validation of a whole-exome sequencing test for simultaneous detection of point mutations, indels and copy-number alterations for precision cancer care.. NPJ Genom Med. 1
G
Rosenbaum JN, Bloom R, Forys JT, Hiken J, Armstrong JR, Branson J, McNulty S, Velu PD, Pepin K, Abel H et al..  2018.  Genomic heterogeneity of ALK fusion breakpoints in non-small-cell lung cancer.. Mod Pathol. 31(5):791-808.
I
Sailer V, Eng KWa, Zhang T, Bareja R, Pisapia DJ, Sigaras A, Bhinder B, Romanel A, Wilkes D, Sticca E et al..  2019.  Integrative Molecular Analysis of Patients With Advanced and Metastatic Cancer.. JCO Precis Oncol. 3
Sailer V, Eng KWa, Zhang T, Bareja R, Pisapia DJ, Sigaras A, Bhinder B, Romanel A, Wilkes D, Sticca E et al..  2019.  Integrative Molecular Analysis of Patients With Advanced and Metastatic Cancer.. JCO Precis Oncol. 3
Sailer V, Eng KWa, Zhang T, Bareja R, Pisapia DJ, Sigaras A, Bhinder B, Romanel A, Wilkes D, Sticca E et al..  2019.  Integrative Molecular Analysis of Patients With Advanced and Metastatic Cancer.. JCO Precis Oncol. 3
R
Xing D, Liu Y, Park HJin, Baek I, Tran H, Cheang G, Novo J, Dillon J, Matoso A, Farmer E et al..  2019.  Recurrent genetic alterations and biomarker expression in primary and metastatic squamous cell carcinomas of the vulva.. Hum Pathol. 92:67-80.
U
Saab J, Zia H, Mathew S, Kluk M, Narula N, Fernandes H.  2017.  Utility of Genomic Analysis in Differentiating Synchronous and Metachronous Lung Adenocarcinomas from Primary Adenocarcinomas with Intrapulmonary Metastasis.. Transl Oncol. 10(3):442-449.